Seven Fleet Capital Management LP Buys Shares of 33,300 Xenon Pharmaceuticals Inc. $XENE

Seven Fleet Capital Management LP purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 33,300 shares of the biopharmaceutical company’s stock, valued at approximately $2,084,000.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Xenon Pharmaceuticals in the 2nd quarter valued at $454,057,000. Jupiter Topco LLC purchased a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at $252,673,000. Holocene Advisors LP acquired a new position in Xenon Pharmaceuticals in the second quarter valued at $56,637,000. Wellington Management Group LLP increased its stake in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Xenon Pharmaceuticals by 1,968.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after buying an additional 820,608 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Buying and Selling

In related news, Director Steven Gannon sold 10,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total transaction of $640,600.00. Following the sale, the director owned 1,870 shares in the company, valued at $119,792.20. This represents a 84.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,512 shares of company stock worth $774,088 over the last quarter. 2.91% of the stock is owned by company insiders.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $63.79 on Thursday. The firm has a fifty day moving average of $62.86 and a two-hundred day moving average of $56.22. The firm has a market cap of $6.17 billion, a P/E ratio of -13.46 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 1-year low of $35.60 and a 1-year high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the prior year, the firm posted ($1.07) EPS. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $74.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Needham & Company LLC decreased their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, Royal Bank Of Canada reduced their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $77.13.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.